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Alteration to motor performance following central neurological injury is a common clinical 
feature often characterised by weakness.  Weakness and reduced motor control are important 
contributors to reduced activity level function in these individuals. However, spasticity is a 
further feature, which may contribute to disability and be a distressing symptom.   
 
The upper motor neurone (UMN) syndrome is a result of damage to the central nervous system 
and consists of what are termed positive features, such as spasticity and negative features, such 
as weakness. Spasticity has been defined as a motor disorder and one component of the UMN 
syndrome by Lance (Lance 1980). The EU-SPASM group have addressed some of the limitations 
of the narrower definition by  Lance, and have incorporated both motor and sensory elements, 
resulting in a definition of “disordered sensorimotor control, resulting from an upper motor 
neurone lesion, presenting as intermittent or sustained involuntary activation of muscles” 
(Pandyan et al. 2005). Data on the prevalence of spasticity are varied, but it has been reported 
in between 38% and 42% of patients after stroke (Urban et al. 2010; Sommerfeld et al. 2011), 
13% in traumatic brain injury and 41 to 66% in people with Multiple Sclerosis (Martin A et al. 
2014).  
 
Spasticity may present a significant clinical problem in terms of limiting function at the level of 
activity performance by the individual, otherwise known as ‘active function’ (Sheean 2001). 
Alternatively it may impact on carrying out care tasks by a caregiver or by the person themselves 
to a paretic limb, otherwise known as ‘passive function’ (Sheean 2001). Spasticity can also have 
further negative symptomatic implications such as pain.  
 
Many individuals with central nervous system damage may exhibit elements of spasticity and 
other associated features of the UMN syndrome, but this doesn’t always require intervention. In 
some instances spasticity may actually be useful, for example enabling standing on an otherwise 
weak leg. The key element in management is therefore to ask, ‘what will be gained with 
intervention?’ or to put the question another way ‘what is the goal?’ 
 
 
 
Assessment  
Assessment of spasticity is commonly undertaken using clinician reported measures such as the 
Modified Ashworth Scale (MAS) or the Tardieu Scale (TS).  These methods have limitations due 
to challenges with both validity and reliability. The MAS in particular conflates resistance to 
passive stretch with spasticity, when spasticity is only one factor impacting on resistance. Both 
scales, when tested also have limited inter-rater reliability. Quantification of resistance to 
passive stretch using force measurement and evaluation of associated muscle activity using 
electromyogram has been demonstrated. These methods have limitations for application in 
daily clinical practice due to the time and equipment required. However these assessments are 
becoming more clinically accessible, and maybe more practical for use in the future. 
Goal attainment scaling is increasingly used as a method to plan treatment and evaluate 
outcome of focal treatment for limb spasticity (Ashford and Turner-Stokes 2006; Ashford and 
Turner-Stokes 2009; Turner-Stokes et al. 2010). Goals for treatment of spasticity are widely 
diverse, depending on the individual aspirations and priorities of the patient and/or their family. 
They may be directed at reducing impairment (e.g. preventing contractures and deformity), 
improving activities (such as personal care) or use of the limb for participatory activities (such as 
work, hobbies, recreation etc.). In other words, goals may be directed at achieving change at any 
level of the World Health Organisation (WHO) International Classification of Function, Disability 
and Health (ICF), but most commonly in activity for both passive and active function. 
Goal Attainment Scaling has now been used as the primary outcome measure in two large multi-
centre trials of focal spasticity intervention in the upper limb, the BEST study (Ward AB et al. 
2014) and the ULIS II study (Turner-Stokes et al. 2013). Through these studies GAS 
demonstrated clinically important change in outcome for people with upper limb spasticity 
following intervention. 
 
Goal setting is only one element of treatment planning and outcome evaluation.  In addition to 
detailed goal setting and attainment, it is also key to quantify improvements against relevant 
standardised measures. This then enables not only evaluation of goal attainment, but 
quantification of goal improvements against a recognised, often patient-reported, measure of 
functional change. 
 
Rehabilitation  
Alongside the systematic setting and evaluation of patient-directed goals, understanding what 
treatment is received and how it is best applied is essential to achieving the best outcomes. 
There is still limited understanding of the combined, complex intervention provided in the 
physical rehabilitation of those with spasticity. To deliver ‘best practice’ it is key that we 
examine which interventions are used and work best to begin to develop a clearer model of 
practice. In spasticity and associated contracture management, this issue becomes challenging 
when a combination of multiple physical and pharmacological interventions are often used and 
relate to the wider rehabilitation that individuals receive, not just the direct management of 
spasticity.   
Evaluation of which treatments are used and effective in practice for spasticity management is 
therefore important to model, before further formal evaluation of those treatments can be 
undertaken in this context. Categorisation of goals for focal spasticity intervention has identified 
consistent goal areas which may be associated with particular types of physical intervention 
(Ashford et al. 2015). Achievement of spasticity treatment goals which are categorised to 
‘passive function’ improvement, may be associated with stretch interventions such as serial 
casting, whereas for ‘active function’ improvements, practicing functional tasks maybe the key 
element. A previous Cochrane review identified 'low level' evidence for the effectiveness of 
outpatient rehabilitation in improving active function and impairments following botulinum 
toxin for upper limb spasticity in adults with chronic stroke (Demetrios et al. 2013). In a further 
Cochrane review evaluating non pharmacological interventions for spasticity in multiple 
sclerosis, there was also 'low level' evidence for physical activity programmes used in isolation 
or in combination with other interventions (pharmacological or non-pharmacological) in 
improving outcomes (Amatya et al. 2013). Further research is however required before firm 
conclusions can be drawn.   
 
A trial to evaluate ‘self-rehabilitation’ (i.e. independent practice) for gait rehabilitation in those 
with chronic stroke and spasticity has suggested that a standardised self-rehabilitation 
programme constitutes a useful approach with enhanced outcome when supported by 
botulinum toxin administration (Roche et al. 2015). This gives some additional support that at 
least for goals directed at ‘active function’ task performance such as walking, therapy focused 
on practicing this is critical to goal achievement. 
 
Future perspectives  
A theoretical framework, possibly based around the selected goals for treatment, might be one 
way of modelling when certain interventions should be applied. Cohort studies evaluating ‘real-
life’ practice, with detailed capture of therapy interventions and how they are applied could 
then be linked back to the goal category for intervention. With sufficient participant numbers, 
over time, a more complete model of when different types of physical intervention should be 
applied and the costs of providing these should be possible to generate.  It then becomes 
possible and useful to evaluate these complex interventions through randomised controlled trial 
methodology.   
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